1. Home
  2. UAA vs STOK Comparison

UAA vs STOK Comparison

Compare UAA & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UAA

Under Armour Inc.

HOLD

Current Price

$4.66

Market Cap

1.9B

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$24.97

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAA
STOK
Founded
1996
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
UAA
STOK
Price
$4.66
$24.97
Analyst Decision
Hold
Strong Buy
Analyst Count
27
14
Target Price
$6.27
★ $46.46
AVG Volume (30 Days)
★ 8.3M
782.2K
Earning Date
11-06-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 92.73
EPS
★ N/A
N/A
Revenue
★ $4,966,370,000.00
$184,420,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.24
$39.98
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 404.50
52 Week Low
$4.13
$20.32
52 Week High
$8.15
$40.22

Technical Indicators

Market Signals
Indicator
UAA
STOK
Relative Strength Index (RSI) 44.07 45.36
Support Level $4.22 $24.21
Resistance Level $5.39 $33.61
Average True Range (ATR) 0.18 1.33
MACD 0.02 0.35
Stochastic Oscillator 5.81 56.19

Price Performance

Historical Comparison
UAA
STOK

About UAA Under Armour Inc.

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: